ArticleScientific reports2025
Frankincense oil nanoemulsion induces selective cytotoxicity and over ROS-mediated oxidative stress and apoptotic DNA damage in Hep-G2 hepatic cancer cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Candicidal Effect of a Nanoemulsion Based on the Essential Oil of the Medicinal PlantPharmaceuticals (Basel, Switzerland) · 2026Article
- Clinical Potential of Essential Oils: Cytotoxicity, Selectivity Index and Antimicrobial Activity Against Gram-Negative ESKAPEE Pathogens.Antibiotics (Basel, Switzerland) · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Frankincense oil nanoemulsion (FONE) exhibits high bioavailability, enhanced cellular uptake, and improved kinetic stability, making it a promising candidate for therapeutic applications. However, its potential effects on hepatocellular carcinoma (HCC) remain insufficiently explored. This study consequently investigated the cytotoxic and apoptotic activities of FONE on human hepatocellular carcinoma (Hep-G2) cells, focusing on cell viability, oxidative stress, DNA damage, and the regulation of apoptosis-related genes. Cell viability and proliferation were evaluated in Hep-G2 hepatic cancer cells and normal human skin fibroblasts (HSF) using the Sulforhodamine B (SRB) assay. Oxidative stress markers, DNA damage, and apoptotic gene expression were assessed through biochemical analysis, alkaline comet assay, and quantitative real-time PCR (qRT-PCR), respectively. Intracellular reactive oxygen species (ROS) levels were measured using 2,7-dichlorofluorescin diacetate (2,7-DCFH-DA) staining. Treatment with FONE at concentrations of 0.1, 1, 10, 100, and 1000 µg/ml for 48 h caused a significant, concentration-dependent reduction in Hep-G2 cell viability, with a half-maximal inhibitory concentration (IC50) of 176.14 µg/ml, while showing minimal cytotoxicity in HSF cells (IC50 = 515.7 µg/ml). Mechanistic investigations revealed that exposure to FONE IC50 concentration (176.14 µg/ml) significantly elevated ROS level, DNA damage, and lipid peroxidation (malondialdehyde level), accompanied by a marked decline in antioxidant defenses, including glutathione content and glutathione peroxidase activity. Gene expression analysis showed notable upregulation of pro-apoptotic genes p53 and Bax, alongside a strong downregulation of the anti-apoptotic gene Bcl-2, in a concentration-dependent manner. FONE exerts selective cytotoxic effects against Hep-G2 cells, mediated by ROS-induced oxidative stress, DNA damage, and apoptosis induction. These findings highlight FONE's potential as a targeted therapeutic agent for hepatocellular carcinoma. Further in vivo investigations and clinical evaluations are recommended to validate its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.